Phase III trial of custirsen in combination with carboplatin and paclitaxel as first-line therapy in patients with advanced, unresectable non-small cell lung cancer.

Trial Profile

Phase III trial of custirsen in combination with carboplatin and paclitaxel as first-line therapy in patients with advanced, unresectable non-small cell lung cancer.

Not stated
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Custirsen (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Sep 2012 Status changed from not yet recruiting to unconfirmed.
    • 10 Mar 2011 Planned number of patients changed to 950.
    • 23 Dec 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top